% 0期刊文章%尼古拉斯Zalewski %一个伊利亚Sechi %一个肖恩Pittock安德鲁·麦肯% %一个塞尔吉奥·法拉利%萨尔瓦多摩纳哥% Eoin弗拉纳根%一个萨拉Mariotto Alejandro Rabinstein % % T血清神经丝轻链水平区分从炎症性脊髓炎脊髓梗死(2620)% D J神经病学2020% % P V 94% 2620% N % X 15补充目的:调查是否血清神经丝轻链(NfL)水平区分从炎症性脊髓炎脊髓梗死(SCI)。首页背景:自然科学引起的急性脊髓病目前没有特定的生物标志物。Aquaporin-4 (AQP4)免疫球蛋白g -相关替代急性脊髓炎是一个特别严重的脊髓病病原学与功能重叠的SCI,并可靠地诊断出患有AQP4-IgG血清阳性。我们假设急性血清NfL水平(中枢神经系统的神经元损伤的生物标志物)将在SCI高于AQP4-IgG-associated脊髓炎,因此可能有用的诊断生物标记来区分SCI和炎症性脊髓炎。设计/方法:我们回顾性梅奥诊所的患者:1)科学;或2)首次治疗AQP4-IgG-associated脊髓炎临床表现;和3)存储血清样本获得≤2个月开始。血清NfL维罗纳大学水平评估神经病理学实验室(SIMOA Quanterix)盲评。代表矢状截脊髓病变区域手动绘制。结果:28例患者包括:SCI, 17;AQP4-IgG-associated脊髓炎11。年龄中位数(范围)血清采样(57 [42 - 86]vs 59[14 - 73]年;p = 0.6),女性性别的频率(8/17(47%)和9/11 (82%); p=0.12), and longitudinally extensive lesions (>3 contiguous vertebral-body segments) on MRI (10/16 [63%] and 9/11 [82%]; p=0.4) were similar in the two groups. Serum NfL levels in patients with SCI (median 224.83 [range, 14.26–2793.41] pg/mL) far exceeded those with AQP4-IgG-associated myelitis (median 56.16 [range, 8.17–687.22] pg/mL); p=0.015. The ratio of NfL levels to cross-sectional lesion area showed high predictive accuracy for SCI with values greater than 0.54 yielding 100% specificity and 94% sensitivity for SCI (AUC=0.99).Conclusions: The ratio of serum NfL/lesion area reliably distinguished SCI from AQP4-IgG myelitis. Serum NfL/lesion area may be a useful biomarker to differentiate SCI from alternative acute myelopathy etiologies, such as inflammatory myelitis.Disclosure: Dr. Zalewski has nothing to disclose. Dr. Sechi has nothing to disclose. Dr. McKeon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grifols, Medimmune, and Euroimmun. Dr. McKeon has received royalty, license fees, or contractual rights payments from Pending patents: MAP1B, Kelch-like-protein 11, GFAP and MAP1B. Dr. McKeon has received research support from Medimmune, Euroimmun but has not received personal compensation.. Dr. Pittock has received personal compensation from Alexion, Grifols, Euroimmun, MedImmune/Viela Bio Dr. Pittock has received research support from Alexion, Grifols, Euroimmun, MedImmune/Viela BioDr. Ferrari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Shire and Sanofi Genzyme.Dr. Monaco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Honoraria from Biogen. Dr. Flanagan has received research support from Medimmune/Viela Bio.Dr. Rabinstein has nothing to disclose. Dr. Mariotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck for attending a neurological meeting. %U